Lanier Olivia L, Pérez-Herrero Edgar, Andrea Abielle P D ', Bahrami Kiana, Lee Elaine, Ward Deidra M, Ayala-Suárez Nilaya, Rodríguez-Méndez Sheyla M, Peppas Nicholas A
Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA.
iScience. 2022 Oct 10;25(11):105326. doi: 10.1016/j.isci.2022.105326. eCollection 2022 Nov 18.
Hematological cancers such as leukemia, lymphoma, and multiple myeloma have traditionally been treated with chemo and radiotherapy approaches. Introduction of immunotherapies for treatment of these diseases has led to patient remissions that would not have been possible with traditional approaches. In this critical review we identify main disease characteristics, symptoms, and current treatment options. Five common immunotherapies, namely checkpoint inhibitors, vaccines, cell-based therapies, antibodies, and oncolytic viruses, are described, and their applications in hematological cancers are critically discussed.
白血病、淋巴瘤和多发性骨髓瘤等血液系统癌症传统上采用化疗和放疗方法进行治疗。免疫疗法用于治疗这些疾病后，已使患者实现缓解，而这用传统方法是不可能实现的。在这篇批判性综述中，我们确定了主要的疾病特征、症状和当前的治疗选择。描述了五种常见的免疫疗法，即检查点抑制剂、疫苗、细胞疗法、抗体和溶瘤病毒，并对它们在血液系统癌症中的应用进行了批判性讨论。
